久久一区二区三区四区_欧美高清dvd_日韩欧美在线看_国产精品欧美一区二区_av天天看_欧美精品免费观看二区

美國PDL BioPharma (PDL)
Protein Design Labs Inc.(PDLI)， 是一個以研發(fā)人類單株抗體(Monoclonal Antibody)基因療法為主的新興生技公司。 PDL獨家生產(chǎn)了多種微分子化合物和抗體， 除了目前在臨床實驗階段的SMART Anti-CD3抗體(治療免疫過敏和抗排斥用)、 Ostavir抗體(治療B型肝炎感染)和M195(治療血癌用)的研發(fā)計劃外， PDL已有多項產(chǎn)品/專利授權(quán)給二十多家合作藥廠，市場遍及美國、歐洲及日本。

由于PDL獨家擁有抗體人類化(antibody humanization pateuts)的專利和服務項目， 因此公司的盈收除了產(chǎn)品的販售外，有相當大的比例是由授權(quán)相關生技藥廠將他們的蛋白質(zhì)抗體轉(zhuǎn)換成適用人體用途的權(quán)利金而來。舉例來說，羅氏(Roche)藥廠的Zenapax、 醫(yī)學免疫公司的(Medimmune, Inc) 的Synagis和基因科技公司(Genentech)的Herceptin的量產(chǎn)和市場化都為PDL帶來了可觀的利潤。

除了開拓和擴展現(xiàn)有的"人類化"(humanized)系列的抗體外，目前PDL也與史丹佛(Stanford)醫(yī)學院的微生物及免疫實驗所共同研發(fā)能夠有效對付抗藥性病菌的新型抗生素。其他的研發(fā)合作對象包括伊萊·利理和羅式(Roche)、日本器官(Nippon Organon)、BioNet GmbH等，合作的項目多以合成和代工新蛋白質(zhì)(Noval Protein)為主。

PDL的研究、臨床和行政管理機構(gòu)皆位于加州的Fremont市。其生產(chǎn)線則位于明尼蘇達州的Plymouth市。至2001年中期，PDL擁有262名員工和總資產(chǎn)57億美元。股票于美國拿斯達克店頭市場交易，掛牌名稱"PDLI"。

PDL BioPharma (PDL) pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases.

Our primary assets are our antibody humanization patents and royalty assets which consist of our Queen et al patents and license agreements with numerous biotechnology and pharmaceutical companies pursuant to which we have licensed certain rights under our Queen et al patents.

PDL is focused on maximizing the value of our antibody humanization patents and related assets. We receive royalties on sales of a number of humanized antibody products marketed today, and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. The company intends to distribute these antibody humanization royalty revenues, net of any operating expenses, debt service and income taxes, to our stockholders. Under the right conditions, and at the right time, PDL will explore a monetization transaction when market conditions warrant.